Clinical Evaluation of Remimazolam Combined with Thoracic Paravertebral Block in Thoracoscopic Surgery for Lung Cancer
Objective To investigate the clinical effect of remimazolam combined with thoracic paravertebral block(TPVB)in thoracoscopic surgery for lung cancer.Methods A total of 122 lung cancer patients who planned to undergo thoracoscopic surgery admitted to the NO.2 Hospital of Baoding from October 2021 to June 2023 were selected and randomly divided into the control group and the observation group,with 61 cases in each group.The patients in the two groups all underwent the thoracoscopic surgery and TPVB,the patients in the control group received conventional anesthetic regimen,while the patients in the observation group received other conventional anesthetic regimen including remimazolam besylate.Results Compared with those in the control group,the time from surgery completion to extubation,indwelling time of drainage tube and hospital stay in the observation group significantly shortened,the total drainage volume and proportion of patients receiving rescue analgesia significantly decreased(P<0.05).Compared with those in the control group,the mean arterial pressure(MAP),heart rate(HR)and Visual Analogue Scale(VAS)scores at 24 h and 72 h after surgery in the observation group significantly decreased,and the Mini-Mental State Examination(MMSE)scale scores significantly increased(P<0.05).Compared with those in the control group,the cardiac troponin I(cTnI),lactoperoxidase(LPO)and C-reactive protein(CRP)levels at 72 h after surgery significantly decreased in the observation group(P<0.05).The incidence of postoperative adverse reactions in the observation group was 8.20%,which was significantly lower than 19.67%in the control group(P<0.05).Conclusion Remimazolam combined with TPVB in thoracoscopic surgery for patients with lung cancer can improve the analgesic effects and hemodynamic stability,relieve cognitive impairment,postoperative myocardial injury,lipid metabolism disorders and inflammatory reactions.